Clinical Trial

Prospective Study of Classification and Activity Assessment of Psoriatic Arthritis Based on Power Doppler (PD) Ultrasonography (PDUS)

Recruiting
View on ClinicalTrials.gov →
Summary
Psoriatic arthritis (PsA) is a complex inflammatory disease with heterogeneous clinical features, which complicates psoriasis in 30% of patients. PsA involves multiple tissues and clinical domains including skins and nails as well as arthritis, spondylitis, enthesitis, and dactylitis. Power Doppler (PD) ultrasonography (PDUS) is a sensitive non-invasive imaging technology used to assess disease activity and treatment response in PsA. This is a prospective, observational, open-label study to investigate disease activity, therapeutic response and bone destruction based on ultrasonography findings in patients with PsA.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-12-11; most recent amendment 2024-12-18.
Status change: Active, Not Recruiting → Recruiting 2024-12-12
Trial Details
NCT Number NCT06730334
Lead Sponsor Nanjing Medical University
Conditions Psoriatic Arthritis, Secukinumab, Ultrasonography
Enrollment 400 participants
Start Date 2023-09-01
Primary Completion 2026-09-01 (estimated)
Study Completion 2028-06-01 (estimated)
Updated on ClinicalTrials.gov 2024-12-20